The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Evan Seigerman - BMO Capital Markets - Analyst
: Hi, guys. Thank you so much for taking my question. Really great to see the progress on the phase to be. You know, I'd really like to touch on some
of the trial design especially for the second trial. What do you hope to really gain from that high dose? I know that it's more exploratory. But do
you think you'll be able to fully understand the benefit of, say that 240 mg dose, you know, at the end at the very tail end? Or is it really just helping
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
Question: Yasmeen Rahimi - Piper Sandler - Analyst
: Good afternoon team. Thank you so much for all the great updates. I guess if you based on your modeling of existing data and that dose optimization
between or dose titration differences between study one and study two, what would you extrapolate the magnitude of weight loss and discontinuation
rates to be between access one and access to, I guess? Is it if you model both out and you both powered them? Could you talk about your expectation
both from a weight loss magnitude as well as the G I dollar of one versus two?
Question: Roger Song - Jefferies - Analyst
: Great congrats for starting the Phase 2b and then thank you for taking the question. So maybe just to follow up on the previous question. So given
you have a multiple dosing regimen to test, can you clarify the potential phase three? Look like you will move forward one dose regimen or multiple,
will this phase three dosing regimen coming from A&A two or you will have a longer, you will have a longer duration for phase three, you may test
different regimen for higher dose if you choose to. Thank you.
Question: Prakhar Agrawal - Cantor Fitzgerald - Analyst
: Hi. Thank you so much for taking the questions and great progress on all the, all the face two design. Maybe just talk about the stat plan on how
it will incorporate those reductions due to tolerability, and how will it compare versus (inaudible) on Phase 2 trials? And had a couple of more.
Question: Prakhar Agrawal - Cantor Fitzgerald - Analyst
: Got it, and lastly given all these different ongoing trial, given these ongoing trials, what are the implications on your partnership discussions? And
when would be the right time to get a partner on board? Thank you.
Question: Seamus Fernandez - Guggenheim - Analyst
: Thanks so much. So actually interested to ask a few questions on the pipeline ray. Just hoping to get a better understanding, you have a number
of Phase 2 ready assets. Do you see an opportunity to advance additional exploratory studies with you know, your April and molecule in combination
prior to potentially seeing some advancement towards your Amylin and you know, as your Amylin DC moves forward and just also you mentioned
a number of other potential programs, you know, Glucagon as well as GIP. You know, just interested to know where you're most excited to see a
next molecule potentially emerge or where we might see a next molecule emerge within the portfolio.
Question: Myriam Belghiti - LifeSci Capital - Analyst
: Thank you and congrats on the progress.
I was wondering how much better you think you can get the tolerability with the start low go slow approach? Do you have a target profile in mind
for the 120 mg dose and higher for what you want to see in terms of GIAE discontinuation or dosehold?
| 
